Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Pharmaceutical Grade Sodium Chloride
... 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Dialysis End-Use, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$417.5 Million by the ... Read More
-
Intermediate Bulk Container
... at a CAGR of 5.2% over the analysis period 2024-2030. Chemical End-Use, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$6.4 Billion by the end of ... Read More
-
Life Sciences BPO
... at a CAGR of 6.5% over the analysis period 2024-2030. Pharmaceutical Outsourcing Services, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$281.8 Billion by the end ... Read More
-
Sterols
... 5.8% over the analysis period 2024-2030. Vegetable Oil Source, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$937.0 Million by the end of the analysis period. ... Read More
-
Sanitary Valves
... CAGR of 3.4% over the analysis period 2024-2030. Control Valves, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$223.4 Million by the end of the analysis ... Read More
-
Healthcare Distribution
... CAGR of 13.5% over the analysis period 2024-2030. Pharmaceutical Distribution, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.3 Trillion by the end of the analysis ... Read More
-
Angina Pectoris Drugs
... at a CAGR of 4.5% over the analysis period 2024-2030. Beta Blockers, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$9.6 Billion by the end of ... Read More
-
Antiemetic Drugs
... CAGR of 5.4% over the analysis period 2024-2030. Chemotherapy Application, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.2 Billion by the end of the analysis ... Read More
-
Empty Capsules
... CAGR of 5.5% over the analysis period 2024-2030. Gelatin Capsules, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$3.5 Billion by the end of the analysis ... Read More
-
Healthcare Cold Chain Logistics
... 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$11.1 Billion by the end ... Read More
-
Chronic Kidney Disease (CKD) Drugs
... Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antihypertensives, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$6.0 Billion by ... Read More
-
Heart Failure Drugs
... at a CAGR of 12.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 16.3% CAGR The Heart Failure Drugs market in the U.S. ... Read More
-
Benign Prostatic Hyperplasia (BPH) Drugs
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Alpha-Blockers, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$7.4 Billion by ... Read More
-
Healthcare Analytical Testing Services
... 2030, growing at a CAGR of 9.7% over the analysis period 2024-2030. Bioanalytical Testing Services, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$2.6 Billion by ... Read More
-
Alzheimer’s Disease Drugs
... at a CAGR of 5.6% over the analysis period 2024-2030. Donepezil Drugs, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$5.2 Billion by the end of ... Read More
-
Vial Adaptors for Reconstitution Drug
... Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Polycarbonate Material, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.3 Billion ... Read More
-
Pharmerging
... 9.7% over the analysis period 2024-2030. Pharmaceutical Pharmerging, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth ... Read More
-
Tangential Flow Filtration
... at a CAGR of 12.0% over the analysis period 2024-2030. Single-Use Systems, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Semi-Automatic Filling Equipment
... at a CAGR of 6.6% over the analysis period 2024-2030. Food & Beverages End-Use, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$2.0 Billion by the ... Read More
-
Campesterol
... 8.5% over the analysis period 2024-2030. Food Ingredients Application, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$143.1 Million by the end of the analysis period. ... Read More
-
Anti-Platelet Agents
... CAGR of 6.7% over the analysis period 2024-2030. Hospital Pharmacies Distribution Channel, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$2.3 Billion by the end of ... Read More
-
Parkinson’s Disease Drugs
... at a CAGR of 6.5% over the analysis period 2024-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$4.6 Billion by the end of ... Read More
-
Microencapsulation Market by Shell Material (Polymers, Gums & Resins, Lipids, Carbohydrates, Proteins), Technology, Core Material, Core Material Form, End-Use Industry, Functionality, and Region - Global Forecast to 2029
... AI technologies include advanced data analysis and predictive modeling that enables the manufacturers to achieve optimization of the microencapsulation techniques, mainly spray drying and coacervation. This can result in new formulations with tailored properties where ... Read More
-
Healthcare Contract Management Software
... 2030, growing at a CAGR of 19.3% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 20.1% CAGR and reach US$7.1 Billion by the ... Read More
-
Native Collagen
... CAGR of 5.9% over the analysis period 2024-2030. Bovine Source, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$130.6 Million by the end of the analysis ... Read More
Research Assistance
